Download PDF
Klin Monbl Augenheilkd 2015; 232(1): 79-84
DOI: 10.1055/s-0034-1383197
Statement
Georg Thieme Verlag KG Stuttgart · New York

Leitlinie des Berufsverbands der Augenärzte Deutschlands e. V. und der Deutschen Ophthalomologischen Gesellschaft: Leitlinie Nr. 24a: Uveitis intermedia (Stand: Juli 2014)[*]

F. Mackensen
,
L. Baydoun
,
J. Garweg
,
T. Hudde
,
A. Heiligenhaus
Further Information

Publication History

Publication Date:
22 January 2015 (online)

Also available at
    Permissions and Reprints

Uveitis intermedia

Leitlinien sind Orientierungshilfen im Sinne von „Handlungs- und Entscheidungskorridoren“, von denen in begründeten Fällen abgewichen werden kann oder sogar muss. Sie beschreiben, was Augenärzte für eine angemessene Patientenversorgung in der Praxis für geboten halten. Dies entspricht in vielen Fällen nicht dem Leistungsniveau der gesetzlichen Krankenversicherung in Deutschland (siehe Präambel).

* Dieser Beitrag wird ebenfalls in der Zeitschrift Der Ophthalmologe, Springer-Verlag, Berlin Heidelberg 2014, 10.1007/s00347-014-3198-6 veröffentlicht.


 

  • Literatur

  • 1 Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-516
    CrossrefPubMedGoogle Scholar
  • 2 Suhler EB, Lloyd MJ, Choi D et al. Incidence and prevalence of uveitis in Veterans Affairs Medical Centers of the Pacific Northwest. Am J Ophthalmol 2008; 146: 890e8-896e8
    PubMedGoogle Scholar
  • 3 Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol 1962; 68: 502-514
    CrossrefPubMedGoogle Scholar
  • 4 Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 2004; 111: 491-500 (discussion 500)
    CrossrefPubMedGoogle Scholar
  • 5 Mortensen KK, Goldschmidt SA, Uveitis E. Eine epidemiologische Untersuchung. Ber Dtsch Ophthalmol Ges 1981; 78: 97-101
    PubMedGoogle Scholar
  • 6 Vadot E. Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 1992; 23: 33-34
    PubMedGoogle Scholar
  • 7 Tran VT, Auer C, Guex-Crosier Y et al. Epidemiological characteristics of uveitis in Switzerland. Int Ophthalmol 1994; 18: 293-298
    CrossrefPubMedGoogle Scholar
  • 8 Saari KM, Paivonsalo-Hietanen T, Vaahtoranta-Lehtonen H et al. Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol Scand 1995; 73: 345-349
    PubMedGoogle Scholar
  • 9 Miettinen R. Incidence of uveitis in Northern Finland. Acta Ophthalmol 1977; 55: 252-260
    PubMedGoogle Scholar
  • 10 Manthey KF. Intraokuläre Entzündungen. Stuttgart: Ferdinand Enke; 1988
    Google Scholar
  • 11 Jakob E, Reuland MS, Mackensen F et al. Uveitis subtypes in a german interdisciplinary uveitis center–analysis of 1916 patients. J Rheumatol 2009; 36: 127-136
    PubMedGoogle Scholar
  • 12 McCannel CA, Holland GN, Helm CJ et al. Causes of uveitis in the general practice of ophthalmology. UCLA Community-Based Uveitis Study Group. Am J Ophthalmol 1996; 121: 35-46
    CrossrefPubMedGoogle Scholar
  • 13 Boskovich SA, Lowder CY, Meisler DM et al. Systemic diseases associated with intermediate uveitis. Cleve Clin J Med 1993; 60: 460-465
    CrossrefPubMedGoogle Scholar
  • 14 Bonfioli AA, Damico FM, Curi AL et al. Intermediate uveitis. Semin Ophthalmol 2005; 20: 147-154
    CrossrefPubMedGoogle Scholar
  • 15 Vidovic-Valentincic N, Kraut A, Hawlina M et al. Intermediate uveitis: long-term course and visual outcome. Br J Ophthalmol 2009; 93: 477-480
    CrossrefPubMedGoogle Scholar
  • 16 Malinowsk SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993; 100: 818-824 (discussion 825)
    CrossrefPubMedGoogle Scholar
  • 17 Fearnley IR, Rosenthal AR. Fuchsʼ heterochromic iridocyclitis revisited. Acta Ophthalmol Scand 1995; 73: 166-170
    CrossrefPubMedGoogle Scholar
  • 18 Jones NP. Fuchsʼ Heterochromic Uveitis: a reappraisal of the clinical spectrum. Eye (Lond) 1991; 5: 649-661
    CrossrefPubMedGoogle Scholar
  • 19 Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 2001; 46: 195-208
    CrossrefPubMedGoogle Scholar
  • 20 Donaldson MJ, Pulido JS, Herman DC et al. Pars planitis: a 20-year study of incidence, clinical features, and outcomes. Am J Ophthalmol 2007; 144: 812-817
    CrossrefPubMedGoogle Scholar
  • 21 Nussenblatt RB, Palestine AG, Chan CC et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467-471
    CrossrefPubMedGoogle Scholar
  • 22 Ang M, Hedayatfar A, Zhang R et al. Clinical signs of uveitis associated with latent tuberculosis. Clin Experiment Ophthalmol 2012; 40: 689-696
    CrossrefPubMedGoogle Scholar
  • 23 Quentin CD, Reiber H. Fuchs heterochromic cyclitis: rubella virus antibodies and genome in aqueous humor. Am J Ophthalmol 2004; 138: 46-54
    CrossrefPubMedGoogle Scholar
  • 24 de Groot-Mijnes JD, de Visser L, Rothova A et al. Rubella virus is associated with fuchs heterochromic iridocyclitis. Am J Ophthalmol 2006; 141: 212-214
    CrossrefPubMedGoogle Scholar
  • 25 Roesel M, Gutfleisch M, Heinz C et al. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 2009; 42: 81-86
    CrossrefPubMedGoogle Scholar
  • 26 Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 2011; 31: 111-118
    CrossrefPubMedGoogle Scholar
  • 27 Kok H, Lau C, Maycock N et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005; 112: 1916e1-e7
    PubMedGoogle Scholar
  • 28 Angunawela RI, Heatley CJ, Williamson TH et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 2005; 83: 595-599
    CrossrefPubMedGoogle Scholar
  • 29 Lowder C, Belfort jr. R, Lightman S et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011; 129: 545-553
    CrossrefPubMedGoogle Scholar
  • 30 Winterhalter S, Ruokonen P, van der Velden KH et al. [Intravitreal implants: drug carriers and carriers of hope?]. Ophthalmologe 2011; 108: 222-229
    CrossrefPubMedGoogle Scholar
  • 31 Jaffe GJ, Martin D, Callanan D et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113: 1020-1027
    CrossrefPubMedGoogle Scholar
  • 32 Callanan DG, Jaffe GJ, Martin DF et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008; 126: 1191-1201
    CrossrefPubMedGoogle Scholar
  • 33 Kempen JH, Altaweel MM, Holbrook JT et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010; 149: 550e10-561e10
    PubMedGoogle Scholar
  • 34 de Smet MD. Corticosteroid intravitreal implants. Dev Ophthalmol 2012; 51: 122-133
    PubMedGoogle Scholar
  • 35 Soheilian M, Rabbanikhah Z, Ramezani A et al. Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study. J Ocul Pharmacol Ther 2010; 26: 199-206
    CrossrefPubMedGoogle Scholar
  • 36 Cunningham jr. ET, Wender JD. Practical approach to the use of corticosteroids in patients with uveitis. Can J Ophthalmol 2010; 45: 352-358
    CrossrefPubMedGoogle Scholar
  • 37 Taylor SR, Isa H, Joshi L et al. New developments in corticosteroid therapy for uveitis. Ophthalmologica 2010; 224 (Suppl. 01) S46-S53
    CrossrefPubMedGoogle Scholar
  • 38 Whitcup SM et al. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996; 103: 1054-1062 (discussion 1062–1063)
    CrossrefPubMedGoogle Scholar
  • 39 Schilling H, Heiligenhaus A, Laube T et al. Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 2005; 25: 182-188
    CrossrefPubMedGoogle Scholar
  • 40 Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000; 130: 492-513
    CrossrefPubMedGoogle Scholar
  • 41 Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012; 2: 21-28
    CrossrefPubMedGoogle Scholar
  • 42 de Vries J, Baarsma GS, Zaal MJ et al. Cyclosporin in the treatment of severe chronic idiopathic uveitis. Br J Ophthalmol 1990; 74: 344-349
    CrossrefPubMedGoogle Scholar
  • 43 Kacmaz RO, Kempen JH, Newcomb C et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010; 117: 576-584
    CrossrefPubMedGoogle Scholar
  • 44 Nussenblatt RB, Palestine AG, Chan CC et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol 1991; 112: 138-146
    CrossrefPubMedGoogle Scholar
  • 45 Gangaputra S, Newcomb CW, Liesegang TL et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009; 116: 2188e1-2198e1
    PubMedGoogle Scholar
  • 46 Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol 2005; 89: 806-808
    CrossrefPubMedGoogle Scholar
  • 47 Teoh SC, Hogan AC, Dick AD et al. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008; 146: 752-760 760e1–3
    CrossrefPubMedGoogle Scholar
  • 48 Galor A, Jabs DA, Leder HA et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115: 1826-1832
    CrossrefPubMedGoogle Scholar
  • 49 Thorne JE, Jabs DA, Qazi FA et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005; 112: 1472-1477
    CrossrefPubMedGoogle Scholar
  • 50 Doycheva D, Deuter C, Blumenstock G et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm 2011; 19: 431-438
    CrossrefPubMedGoogle Scholar
  • 51 Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS et al. The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 2012; 90: e603-e608
    CrossrefPubMedGoogle Scholar
  • 52 Doycheva D, Zierhut M, Blumenstock G et al. Mycophenolate mofetil in the therapy of uveitic macular edema–long-term results. Ocul Immunol Inflamm 2012; 20: 203-211
    CrossrefPubMedGoogle Scholar
  • 53 Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003; 31: 487-491
    CrossrefPubMedGoogle Scholar
  • 54 Siepmann K, Huber M, Stubiger N et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006; 244: 788-794
    CrossrefPubMedGoogle Scholar
  • 55 Murphy CC, Greiner K, Plskova J et al. Cyclosporine vs. tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005; 123: 634-641
    CrossrefPubMedGoogle Scholar
  • 56 Hogan AC, McAvoy CE, Dick AD et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007; 114: 1000-1006
    CrossrefPubMedGoogle Scholar
  • 57 Pacheco PA, Taylor SR, Cuchacovich MT et al. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 2008; 16: 161-165
    CrossrefPubMedGoogle Scholar
  • 58 Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behcetʼs syndrome. N Engl J Med 1990; 322: 281-285
    CrossrefPubMedGoogle Scholar
  • 59 Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye (Lond) 1998; 12: 783-788
    CrossrefPubMedGoogle Scholar
  • 60 Roy M. Early clinical experience with leflunomide in uveitis. Can J Ophthalmol 2007; 42: 634
    CrossrefPubMedGoogle Scholar
  • 61 Molina C, Modesto C, Martin-Begué N et al. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol 2013; 32: 1673-1675
    CrossrefPubMedGoogle Scholar
  • 62 Mackensen F, Max R, Becker MD. Interferons and their potential in the treatment of ocular inflammation. Clin Ophthalmol 2009; 3: 559-566
    PubMedGoogle Scholar
  • 63 Deuter C, Stubiger N, Zierhut M. Interferon-alpha therapy in noninfectious uveitis. Dev Ophthalmol 2012; 51: 90-97
    PubMedGoogle Scholar
  • 64 Mackensen F, Jakob E, Springer C et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 2013; 156: 478e1-486e1
    PubMedGoogle Scholar
  • 65 Missotten T, van Laar JA, van der Loos TL et al. Octreotide long-acting repeatable for the treatment of chronic macular edema in uveitis. Am J Ophthalmol 2007; 144: 838-843
    CrossrefPubMedGoogle Scholar
  • 66 Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm 2013; 21: 12-20
    PubMedGoogle Scholar
  • 67 Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012; 51 (Suppl. 05) v38-v47
    CrossrefPubMedGoogle Scholar
  • 68 Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol 2005; 140: 1096-1105
    CrossrefPubMedGoogle Scholar